US2024026010A1PendingUtilityA1
Galectin-10 antibodies

Assignee: argenx BVPriority: Apr 13, 2018Filed: Jun 7, 2023Published: Jan 25, 2024
Est. expiryApr 13, 2038(~11.7 yrs left)· nominal 20-yr term from priority
Inventors:Jean-Michel Percier Christophe Blanchetot Michael John Scott Saunders Hans De Haard Sebastian Van Der Woning Emma Persson Bart Lambrecht Savvas Savvides Hamida Hammad Kenneth Verstraete
C07K 16/2851G01N 33/68A61K 2039/505C07K 2317/34C07K 2317/622C07K 2317/64C07K 2317/76C07K 2317/92A61P 11/00C07K 2317/55G01N 2333/4724A61P 11/06A61P 31/00G01N 33/6857
PatentIndex Score
Cited by
References
Claims
Abstract

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
Claims

exact text as granted — not AI-modified
1 - 17 . (canceled) 
     
     
         18 . A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the subject has a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; cystic fibrosis (CF); allergic bronchopulmonary aspergillosis (ABPA); Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia, wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and/or Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         19 . The method of  claim 18 , wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the CDR sequences HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177. 
     
     
         20 . The method of  claim 18 , wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         21 . The method of  claim 18 , wherein the subject has asthma. 
     
     
         22 . The method of  claim 18 , wherein the subject has chronic rhinosinusitis. 
     
     
         23 . A method of reducing the amount of galectin-10 crystals in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and/or Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         24 . The method of  claim 23 , wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a VH and a VL, wherein the VH and VL domains comprise the CDR sequences HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177. 
     
     
         25 . The method of  claim 23 , wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         26 . The method of  claim 23 , wherein the subject has or is suspected of having a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; CF; ABPA; Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia. 
     
     
         27 . The method of  claim 23 , wherein the subject has asthma. 
     
     
         28 . The method of  claim 23 , wherein the subject has chronic rhinosinusitis. 
     
     
         29 . A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the subject has a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; CF; ABPA; Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia, and wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with:
 (a) an antibody or antigen binding fragment thereof comprising a VH and a VL wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:
 (i) HCDR3 comprising SEQ ID NO: 15, HCDR2 comprising SEQ ID NO: 14, HCDR1 comprising SEQ ID NO: 13, LCDR3 comprising SEQ ID NO: 70, LCDR2 comprising SEQ ID NO: 69, and LCDR1 comprising SEQ ID NO: 68; 
 (ii) HCDR3 comprising SEQ ID NO: 18, HCDR2 comprising SEQ ID NO: 17, HCDR1 comprising SEQ ID NO: 16, LCDR3 comprising SEQ ID NO: 72, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 71; 
 (iii) HCDR3 comprising SEQ ID NO: 20, HCDR2 comprising SEQ ID NO: 19, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 75, LCDR2 comprising SEQ ID NO: 74, and LCDR1 comprising SEQ ID NO: 73; 
 (iv) HCDR3 comprising SEQ ID NO: 23, HCDR2 comprising SEQ ID NO: 22, HCDR1 comprising SEQ ID NO: 21, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65; 
 (v) HCDR3 comprising SEQ ID NO: 28, HCDR2 comprising SEQ ID NO: 27, HCDR1 comprising SEQ ID NO: 26, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 79; 
 (vi) HCDR3 comprising SEQ ID NO: 31, HCDR2 comprising SEQ ID NO: 30, HCDR1 comprising SEQ ID NO: 29, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 80; 
 (vii) HCDR3 comprising SEQ ID NO: 33, HCDR2 comprising SEQ ID NO: 32, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 83, and LCDR1 comprising SEQ ID NO: 82; 
 (viii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 35, HCDR1 comprising SEQ ID NO: 34, LCDR3 comprising SEQ ID NO: 87, LCDR2 comprising SEQ ID NO: 86, and LCDR1 comprising SEQ ID NO: 85; 
 (ix) HCDR3 comprising SEQ ID NO: 38, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 37, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 88; 
 (x) HCDR3 comprising SEQ ID NO: 41, HCDR2 comprising SEQ ID NO: 40, HCDR1 comprising SEQ ID NO: 39, LCDR3 comprising SEQ ID NO: 91, LCDR2 comprising SEQ ID NO: 90, and LCDR1 comprising SEQ ID NO: 89; 
 (xi) HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177; 
 (xii) HCDR3 comprising SEQ ID NO: 168, HCDR2 comprising SEQ ID NO: 167, HCDR1 comprising SEQ ID NO: 166, LCDR3 comprising SEQ ID NO: 185, LCDR2 comprising SEQ ID NO: 184, and LCDR1 comprising SEQ ID NO: 183; 
 (xiii) HCDR3 comprising SEQ ID NO: 171, HCDR2 comprising SEQ ID NO: 170, HCDR1 comprising SEQ ID NO: 169, LCDR3 comprising SEQ ID NO: 187, LCDR2 comprising SEQ ID NO: 186, and LCDR1 comprising SEQ ID NO: 180; and 
 (xiv) HCDR3 comprising SEQ ID NO: 176, HCDR2 comprising SEQ ID NO: 175, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 192, LCDR2 comprising SEQ ID NO: 191, and LCDR1 comprising SEQ ID NO: 190; or 
   (b) an antibody comprising a VHH domain comprising the CDR sequences selected from the group consisting of:
 (i) CDR3 comprising SEQ ID NO: 210, CDR2 comprising SEQ ID NO: 209, and CDR1 comprising SEQ ID NO: 208; 
 (ii) CDR3 comprising SEQ ID NO: 213, CDR2 comprising SEQ ID NO: 212, and CDR1 comprising SEQ ID NO: 211; 
 (iii) CDR3 comprising SEQ ID NO: 216, CDR2 comprising SEQ ID NO: 215, and CDR1 comprising SEQ ID NO: 214; 
 (iv) CDR3 comprising SEQ ID NO: 219, CDR2 comprising SEQ ID NO: 218, and CDR1 comprising SEQ ID NO: 217; 
 (v) CDR3 comprising SEQ ID NO: 222, CDR2 comprising SEQ ID NO: 221, and CDR1 comprising SEQ ID NO: 220; 
 (vi) CDR3 comprising SEQ ID NO: 225, CDR2 comprising SEQ ID NO: 224, and CDR1 comprising SEQ ID NO: 223; 
 (vii) CDR3 comprising SEQ ID NO: 228, CDR2 comprising SEQ ID NO: 227, and CDR1 comprising SEQ ID NO: 226; 
 (viii) CDR3 comprising SEQ ID NO: 231, CDR2 comprising SEQ ID NO: 230, and CDR1 comprising SEQ ID NO: 229; 
 (ix) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (x) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xi) CDR3 comprising SEQ ID NO: 238, CDR2 comprising SEQ ID NO: 237, and CDR1 comprising SEQ ID NO: 232; 
 (xii) CDR3 comprising SEQ ID NO: 241, CDR2 comprising SEQ ID NO: 240, and CDR1 comprising SEQ ID NO: 239; 
 (xiii) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xiv) CDR3 comprising SEQ ID NO: 244, CDR2 comprising SEQ ID NO: 243, and CDR1 comprising SEQ ID NO: 242; 
 (xv) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (xvi) CDR3 comprising SEQ ID NO: 247, CDR2 comprising SEQ ID NO: 246, and CDR1 comprising SEQ ID NO: 245; and 
 (xvii) CDR3 comprising SEQ ID NO: 249, CDR2 comprising SEQ ID NO: 248, and CDR1 comprising SEQ ID NO: 217. 
   
     
     
         30 . The method of  claim 29 , wherein the subject has asthma. 
     
     
         31 . The method of  claim 29 , wherein the subject has chronic rhinosinusitis. 
     
     
         32 . A method of reducing the amount of galectin-10 crystals in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with:
 (a) an antibody or antigen binding fragment thereof comprising a VH and a VL wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:
 (i) HCDR3 comprising SEQ ID NO: 15, HCDR2 comprising SEQ ID NO: 14, HCDR1 comprising SEQ ID NO: 13, LCDR3 comprising SEQ ID NO: 70, LCDR2 comprising SEQ ID NO: 69, and LCDR1 comprising SEQ ID NO: 68; 
 (ii) HCDR3 comprising SEQ ID NO: 18, HCDR2 comprising SEQ ID NO: 17, HCDR1 comprising SEQ ID NO: 16, LCDR3 comprising SEQ ID NO: 72, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 71; 
 (iii) HCDR3 comprising SEQ ID NO: 20, HCDR2 comprising SEQ ID NO: 19, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 75, LCDR2 comprising SEQ ID NO: 74, and LCDR1 comprising SEQ ID NO: 73; 
 (iv) HCDR3 comprising SEQ ID NO: 23, HCDR2 comprising SEQ ID NO: 22, HCDR1 comprising SEQ ID NO: 21, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65; 
 (v) HCDR3 comprising SEQ ID NO: 28, HCDR2 comprising SEQ ID NO: 27, HCDR1 comprising SEQ ID NO: 26, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 79; 
 (vi) HCDR3 comprising SEQ ID NO: 31, HCDR2 comprising SEQ ID NO: 30, HCDR1 comprising SEQ ID NO: 29, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 80; 
 (vii) HCDR3 comprising SEQ ID NO: 33, HCDR2 comprising SEQ ID NO: 32, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 83, and LCDR1 comprising SEQ ID NO: 82; 
 (viii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 35, HCDR1 comprising SEQ ID NO: 34, LCDR3 comprising SEQ ID NO: 87, LCDR2 comprising SEQ ID NO: 86, and LCDR1 comprising SEQ ID NO: 85; 
 (ix) HCDR3 comprising SEQ ID NO: 38, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 37, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 88; 
 (x) HCDR3 comprising SEQ ID NO: 41, HCDR2 comprising SEQ ID NO: 40, HCDR1 comprising SEQ ID NO: 39, LCDR3 comprising SEQ ID NO: 91, LCDR2 comprising SEQ ID NO: 90, and LCDR1 comprising SEQ ID NO: 89; 
 (xi) HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177; 
 (xii) HCDR3 comprising SEQ ID NO: 168, HCDR2 comprising SEQ ID NO: 167, HCDR1 comprising SEQ ID NO: 166, LCDR3 comprising SEQ ID NO: 185, LCDR2 comprising SEQ ID NO: 184, and LCDR1 comprising SEQ ID NO: 183; 
 (xiii) HCDR3 comprising SEQ ID NO: 171, HCDR2 comprising SEQ ID NO: 170, HCDR1 comprising SEQ ID NO: 169, LCDR3 comprising SEQ ID NO: 187, LCDR2 comprising SEQ ID NO: 186, and LCDR1 comprising SEQ ID NO: 180; and 
 (xiv) HCDR3 comprising SEQ ID NO: 176, HCDR2 comprising SEQ ID NO: 175, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 192, LCDR2 comprising SEQ ID NO: 191, and LCDR1 comprising SEQ ID NO: 190; or 
   (b) an antibody comprising a VHH domain comprising the CDR sequences selected from the group consisting of:
 (i) CDR3 comprising SEQ ID NO: 210, CDR2 comprising SEQ ID NO: 209, and CDR1 comprising SEQ ID NO: 208; 
 (ii) CDR3 comprising SEQ ID NO: 213, CDR2 comprising SEQ ID NO: 212, and CDR1 comprising SEQ ID NO: 211; 
 (iii) CDR3 comprising SEQ ID NO: 216, CDR2 comprising SEQ ID NO: 215, and CDR1 comprising SEQ ID NO: 214; 
 (iv) CDR3 comprising SEQ ID NO: 219, CDR2 comprising SEQ ID NO: 218, and CDR1 comprising SEQ ID NO: 217; 
 (v) CDR3 comprising SEQ ID NO: 222, CDR2 comprising SEQ ID NO: 221, and CDR1 comprising SEQ ID NO: 220; 
 (vi) CDR3 comprising SEQ ID NO: 225, CDR2 comprising SEQ ID NO: 224, and CDR1 comprising SEQ ID NO: 223; 
 (vii) CDR3 comprising SEQ ID NO: 228, CDR2 comprising SEQ ID NO: 227, and CDR1 comprising SEQ ID NO: 226; 
 (viii) CDR3 comprising SEQ ID NO: 231, CDR2 comprising SEQ ID NO: 230, and CDR1 comprising SEQ ID NO: 229; 
 (ix) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (x) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xi) CDR3 comprising SEQ ID NO: 238, CDR2 comprising SEQ ID NO: 237, and CDR1 comprising SEQ ID NO: 232; 
 (xii) CDR3 comprising SEQ ID NO: 241, CDR2 comprising SEQ ID NO: 240, and CDR1 comprising SEQ ID NO: 239; 
 (xiii) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xiv) CDR3 comprising SEQ ID NO: 244, CDR2 comprising SEQ ID NO: 243, and CDR1 comprising SEQ ID NO: 242; 
 (xv) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (xvi) CDR3 comprising SEQ ID NO: 247, CDR2 comprising SEQ ID NO: 246, and CDR1 comprising SEQ ID NO: 245; and 
 (xvii) CDR3 comprising SEQ ID NO: 249, CDR2 comprising SEQ ID NO: 248, and CDR1 comprising SEQ ID NO: 217. 
   
     
     
         33 . The method of  claim 32 , wherein the subject has a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; CF; ABPA; Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia. 
     
     
         34 . The method of  claim 32 , wherein the subject has asthma. 
     
     
         35 . The method of  claim 32 , wherein the subject has chronic rhinosinusitis. 
     
     
         36 . A method of detecting galectin-10 in a sample obtained from a subject, the method comprising contacting the sample with an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and/or Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         37 . The method of  claim 36 , wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a VH and a VL wherein the VH and VL domains comprise the CDR sequences HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177. 
     
     
         38 . The method of  claim 36 , wherein the antibody or antigen binding fragment thereof binds to an epitope comprising or consisting of Ser2, Leu3, Leu4, Pro5, Pro7, Tyr8, Thr9, Glu10, Ala11, Lys23, Arg25, Met44, Gly86, Gln87, Glu88, Phe89, Glu90, Asn105, Thr123, Gln125, Thr133, Lys134, and Phe135, and wherein the residues are identified with reference to SEQ ID NO:141. 
     
     
         39 . The method of  claim 36 , wherein the sample is mucus, sputum, or tissue from a nasal polyp. 
     
     
         40 . The method of  claim 36 , wherein the subject has or is suspected of having a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; CF; ABPA; Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia. 
     
     
         41 . The method of  claim 36 , wherein the subject has asthma. 
     
     
         42 . The method of  claim 36 , wherein the subject has chronic rhinosinusitis. 
     
     
         43 . The method of  claim 36 , further comprising treating the subject with an antagonist that binds to galectin-10. 
     
     
         44 . A method of detecting galectin-10 in a sample obtained from a subject, the method comprising contacting the sample with:
 (a) an antibody or antigen binding fragment thereof comprising a VH and a VL wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:
 (i) HCDR3 comprising SEQ ID NO: 3, HCDR2 comprising SEQ ID NO: 2, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 58, LCDR2 comprising SEQ ID NO: 57, and LCDR1 comprising SEQ ID NO: 56; 
 (ii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 5, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 61, LCDR2 comprising SEQ ID NO: 60, and LCDR1 comprising SEQ ID NO: 59; 
 (iii) HCDR3 comprising SEQ ID NO: 9, HCDR2 comprising SEQ ID NO: 8, HCDR1 comprising SEQ ID NO: 7, LCDR3 comprising SEQ ID NO: 64, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 62; 
 (iv) HCDR3 comprising SEQ ID NO: 12, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 10, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65; 
 (v) HCDR3 comprising SEQ ID NO: 15, HCDR2 comprising SEQ ID NO: 14, HCDR1 comprising SEQ ID NO: 13, LCDR3 comprising SEQ ID NO: 70, LCDR2 comprising SEQ ID NO: 69, and LCDR1 comprising SEQ ID NO: 68; 
 (vi) HCDR3 comprising SEQ ID NO: 18, HCDR2 comprising SEQ ID NO: 17, HCDR1 comprising SEQ ID NO: 16, LCDR3 comprising SEQ ID NO: 72, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 71; 
 (vii) HCDR3 comprising SEQ ID NO: 20, HCDR2 comprising SEQ ID NO: 19, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 75, LCDR2 comprising SEQ ID NO: 74, and LCDR1 comprising SEQ ID NO: 73; 
 (viii) HCDR3 comprising SEQ ID NO: 23, HCDR2 comprising SEQ ID NO: 22, HCDR1 comprising SEQ ID NO: 21, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65; 
 (ix) HCDR3 comprising SEQ ID NO: 25, HCDR2 comprising SEQ ID NO: 24, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 77, and LCDR1 comprising SEQ ID NO: 76; 
 (x) HCDR3 comprising SEQ ID NO: 28, HCDR2 comprising SEQ ID NO: 27, HCDR1 comprising SEQ ID NO: 26, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 79; 
 (xi) HCDR3 comprising SEQ ID NO: 31, HCDR2 comprising SEQ ID NO: 30, HCDR1 comprising SEQ ID NO: 29, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 80; 
 (xii) HCDR3 comprising SEQ ID NO: 33, HCDR2 comprising SEQ ID NO: 32, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 83, and LCDR1 comprising SEQ ID NO: 82; 
 (xiii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 35, HCDR1 comprising SEQ ID NO: 34, LCDR3 comprising SEQ ID NO: 87, LCDR2 comprising SEQ ID NO: 86, and LCDR1 comprising SEQ ID NO: 85; 
 (xiv) HCDR3 comprising SEQ ID NO: 38, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 37, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 88; 
 (xv) HCDR3 comprising SEQ ID NO: 41, HCDR2 comprising SEQ ID NO: 40, HCDR1 comprising SEQ ID NO: 39, LCDR3 comprising SEQ ID NO: 91, LCDR2 comprising SEQ ID NO: 90, and LCDR1 comprising SEQ ID NO: 89; 
 (xvi) HCDR3 comprising SEQ ID NO: 43, HCDR2 comprising SEQ ID NO: 42, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 92; 
 (xvii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 44, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 97, LCDR2 comprising SEQ ID NO: 96, and LCDR1 comprising SEQ ID NO: 95; 
 (xviii) HCDR3 comprising SEQ ID NO: 47, HCDR2 comprising SEQ ID NO: 46, HCDR1 comprising SEQ ID NO: 45, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71; 
 (xix) HCDR3 comprising SEQ ID NO: 50, HCDR2 comprising SEQ ID NO: 49, HCDR1 comprising SEQ ID NO: 48, LCDR3 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 95; 
 (xx) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 52, HCDR1 comprising SEQ ID NO: 51, LCDR3 comprising SEQ ID NO: 98, LCDR2 comprising SEQ ID NO: 97, and LCDR1 comprising SEQ ID NO: 80; 
 (xxi) HCDR3 comprising SEQ ID NO: 55, HCDR2 comprising SEQ ID NO: 54, HCDR1 comprising SEQ ID NO: 53, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71; 
 (xxii) HCDR3 comprising SEQ ID NO: 162, HCDR2 comprising SEQ ID NO: 161, HCDR1 comprising SEQ ID NO: 160, LCDR3 comprising SEQ ID NO: 179, LCDR2 comprising SEQ ID NO: 178, and LCDR1 comprising SEQ ID NO: 177; 
 (xxiii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 182, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180; 
 (xxiv) HCDR3 comprising SEQ ID NO: 168, HCDR2 comprising SEQ ID NO: 167, HCDR1 comprising SEQ ID NO: 166, LCDR3 comprising SEQ ID NO: 185, LCDR2 comprising SEQ ID NO: 184, and LCDR1 comprising SEQ ID NO: 183; 
 (xxv) HCDR3 comprising SEQ ID NO: 171, HCDR2 comprising SEQ ID NO: 170, HCDR1 comprising SEQ ID NO: 169, LCDR3 comprising SEQ ID NO: 187, LCDR2 comprising SEQ ID NO: 186, and LCDR1 comprising SEQ ID NO: 180; 
 (xxvi) HCDR3 comprising SEQ ID NO: 174, HCDR2 comprising SEQ ID NO: 173, HCDR1 comprising SEQ ID NO: 172, LCDR3 comprising SEQ ID NO: 189, LCDR2 comprising SEQ ID NO: 188, and LCDR1 comprising SEQ ID NO: 180; 
 (xxvii) HCDR3 comprising SEQ ID NO: 176, HCDR2 comprising SEQ ID NO: 175, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 192, LCDR2 comprising SEQ ID NO: 191, and LCDR1 comprising SEQ ID NO: 190; and 
 (xxviii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 193, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180; or 
   (b) an antibody comprising a VHH domain comprising the CDR sequences selected from the group consisting of:
 (i) CDR3 comprising SEQ ID NO: 210, CDR2 comprising SEQ ID NO: 209, and CDR1 comprising SEQ ID NO: 208; 
 (ii) CDR3 comprising SEQ ID NO: 213, CDR2 comprising SEQ ID NO: 212, and CDR1 comprising SEQ ID NO: 211; 
 (iii) CDR3 comprising SEQ ID NO: 216, CDR2 comprising SEQ ID NO: 215, and CDR1 comprising SEQ ID NO: 214; 
 (iv) CDR3 comprising SEQ ID NO: 219, CDR2 comprising SEQ ID NO: 218, and CDR1 comprising SEQ ID NO: 217; 
 (v) CDR3 comprising SEQ ID NO: 222, CDR2 comprising SEQ ID NO: 221, and CDR1 comprising SEQ ID NO: 220; 
 (vi) CDR3 comprising SEQ ID NO: 225, CDR2 comprising SEQ ID NO: 224, and CDR1 comprising SEQ ID NO: 223; 
 (vii) CDR3 comprising SEQ ID NO: 228, CDR2 comprising SEQ ID NO: 227, and CDR1 comprising SEQ ID NO: 226; 
 (viii) CDR3 comprising SEQ ID NO: 231, CDR2 comprising SEQ ID NO: 230, and CDR1 comprising SEQ ID NO: 229; 
 (ix) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (x) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xi) CDR3 comprising SEQ ID NO: 238, CDR2 comprising SEQ ID NO: 237, and CDR1 comprising SEQ ID NO: 232; 
 (xii) CDR3 comprising SEQ ID NO: 241, CDR2 comprising SEQ ID NO: 240, and CDR1 comprising SEQ ID NO: 239; 
 (xiii) CDR3 comprising SEQ ID NO: 236, CDR2 comprising SEQ ID NO: 235, and CDR1 comprising SEQ ID NO: 226; 
 (xiv) CDR3 comprising SEQ ID NO: 244, CDR2 comprising SEQ ID NO: 243, and CDR1 comprising SEQ ID NO: 242; 
 (xv) CDR3 comprising SEQ ID NO: 234, CDR2 comprising SEQ ID NO: 233, and CDR1 comprising SEQ ID NO: 232; 
 (xvi) CDR3 comprising SEQ ID NO: 247, CDR2 comprising SEQ ID NO: 246, and CDR1 comprising SEQ ID NO: 245; and 
 (xvii) CDR3 comprising SEQ ID NO: 249, CDR2 comprising SEQ ID NO: 248, and CDR1 comprising SEQ ID NO: 217; and 
   detecting binding of the antibody or antigen binding fragment thereof to the sample, thereby detecting galectin-10 in the sample.   
     
     
         45 . The method of  claim 44 , wherein the sample is mucus, sputum, or tissue from a nasal polyp. 
     
     
         46 . The method of  claim 44 , wherein the subject has or is suspected of having a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; CF; ABPA; Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia. 
     
     
         47 . The method of  claim 44 , wherein the subject has asthma. 
     
     
         48 . The method of  claim 44 , wherein the subject has chronic rhinosinusitis. 
     
     
         49 . The method of  claim 44 , further comprising treating the subject with an antagonist that binds to galectin-10.
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.